Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0043167 (pertussis)
 19,595 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors show a scientific literary review on Ch. trachomatis pneumonia. A distinctive syndrome pneumonia has been reported in infants infected by Chlamydia (at 2-3 months of age) in genital-urinary infected mothers. The infection may be preceded by conjunctivitis, in apyrexia followed by attacks of coughing pertussis-like. Blood eosinophilia is present. Although favorable prognosis in infancy, erythromycin is the drug of choice shortening the clinical course erythromycin is also recommended in woman infected prevention.
 ...
PMID:[Pulmonary infections in children. III. Pneumonia due to Chlamydia trachomatis]. 809 Jan 37

1. S-1108 granules were administered to 22 children with bacterial infections (8 cases of bronchitis, 1 case of pneumonia, 3 cases of scarlet fever, 2 cases each of tonsillitis, pharyngitis, pertussis, purulent lymphadenitis and impetigo). 2. Clinical efficacies were excellent in 12 patients and good in 7, fair in 1, poor in 1 and unevaluable in 1 with an efficacy rate of 90.5%. 3. Neither side effects nor abnormal laboratory test values were observed. 4. There was no rejection of the drug during the therapy. From the above results, we consider S-1108 in granular form to be a useful and safe drug in the treatment of various bacterial infection in pediatric patients.
 ...
PMID:[A clinical evaluation of S-1108 in the treatment of pediatric infections]. 810 72

S-1108 in a fine granular form was administered in 14 children and its safety and efficacy in bacterial infections were evaluated. Among them, 2 cases of cystitis and 1 case of pneumonia were considered unevaluable for the efficacy. The results obtained are summarized as follows. 1. The overall clinical efficacy rate was 81.8% in the eleven evaluable cases treated with S-1108 fine granules including 5 cases of pharyngitis, 2 cases each of tonsillitis, pertussis and cystitis. 2. Bacteriological efficacy of 100% was achieved against pathogens identified in 5 children including 1 case each of Staphylococcus aureus, Streptococcus pyogenes and Haemophilus influenzae and 2 cases of Escherichia coli. 3. The only abnormal laboratory test results observed were eosinophilia and leukocytopenia in one case each. Diarrhea was recorded in 1 case. Judging from the above results, it appears that S-1108 in the fine granular form is an effective, useful and safe antibiotic of first choice for the treatment of infections in the pediatric field.
 ...
PMID:[Clinical study of S-1108 fine granule in the pediatric field]. 810 74

Acute respiratory infections (ARI) cause more than four million childhood deaths each year in developing countries. In addition to standard case management, vaccines have a great potential for reducing these deaths. Immunization against measles and pertussis, already reaching more than 70% of infants in developing countries, contributes to the prevention of more than one million childhood deaths. New conjugate vaccines against Haemophilus influenzae type b, if shown to be effective against pneumonia in developing countries, could reduce acute lower respiratory infection (ALRI) deaths by 4%. A further 10% reduction could be obtained by the availability of an effective conjugate vaccine against Streptococcus pneumoniae. A safe vaccine against respiratory syncytial virus could also prevent 10% of ALRI deaths. The potential role of other bacterial and viral vaccines needs to be clarified.
 ...
PMID:Current role of vaccination in preventing acute respiratory infections in children in developing countries. 819 21

Pharmacokinetic and clinical studies on S-1108, a new oral cephem antibiotic, were performed in pediatric infections and the following results were obtained. 1. Pharmacokinetics studies Pharmacokinetics of S-1108 was studied in 4 children (3 y 7 m-11 y 1 m) using doses of 2 mg/kg (n = 2) and 4 mg/kg (n = 2). The average peak plasma level was 0.88 microgram/ml at 2 hours after administration of 2 mg/kg and 2.00 micrograms/ml at 3 hours after administration of 4 mg/kg, and plasma half-lives were 1.45 and 0.96 hours, respectively. Average cumulative urinary recovery rates at 0-6 hours were 30.0 and 34.8%, respectively. 2. Clinical studies S-1108 was administered to 32 patients with various infectious diseases (6 with acute tonsillitis, 2 each with pertussis and acute bronchitis, 3 with pneumonia, 4 with scarlet fever, 5 with impetigo contagiosa, 6 with acute urinary infection and 1 each with subcutaneous abscess, impetigo, vulvitis and urethritis) at daily doses between 6-12 mg/kg/day, t.i.d., for 5-12 days. Clinical responses were excellent in 17 patients, good in 13, and poor in 2, and the efficacy rate was 93.8%. Bacteria were identified and 33 strains of 12 species were found. The eradication rate was 93.9%. No side effects were observed in 43 patients. Abnormal laboratory test values were observed in 2 patients, 1 with elevation of eosin. and the other with elevations of GOT and GPT. The results suggest that S-1108 may be a very useful and safe drug for the treatment of pediatric infections.
 ...
PMID:[Studies on S-1108 in pediatric infection]. 830 74

Bacteriological, pharmacokinetic and clinical studies on cefditoren pivoxil (CDTR-PI, ME 1207) in granules, a new oral cephalosporin, were performed in the field of pediatrics. The results are summarized below. 1. Antibacterial activities: Antibacterial activities of CDTR were studied against Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Haemophilus parainfluenzae and Branhamella catarrhalis in comparison with those of cefteram (CFTM), cefixime (CFIX), cefaclor (CCL), cefpodoxime (CPDX) and cefotiam (CTM). MIC80's of CDTR against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, H. parainfluenzae and B. catarrhalis were 1.56, 0.39, < or = 0.025, < or = 0.025, 0.05 and 0.20 micrograms/ml, respectively. These results showed that CDTR has high antibacterial activities against these organisms. 2. Absorption and excretion: Serum concentrations and urinary recovery rates of CDTR-PI (administered in granules) were determined. Upon single oral doses of 3 mg/kg and 6 mg/kg, the peak serum concentrations were 0.5-2.45 micrograms/ml at 2 to 4 hours and 1.79-4.05 micrograms/ml at 1 to 4 hours, respectively, and T 1/2 was 1.07-9.67 hours and 0.99-3.00 hours, respectively. At 8 hours after dosing, serum concentrations were 0-0.87 micrograms/ml with a dose of 3 mg/kg and 0.27-0.73 micrograms/ml with 6 mg/kg. These values indicated that the drug has a dose-dependent pharmacokinetic behavior. Urinary recovery rates in the first 8 hours were 12.9-34.2% with a dose of 3 mg/kg and 11.8-26.9% with 6 mg/kg. 3. Clinical study: Clinical efficacies were examined in a total of 81 cases consisting of 20 cases of acute bronchitis, 13 of acute pneumonia, 21 of tonsillitis, 5 of pharyngitis, 7 of scarlet fever, 2 each of impetigo, otitis media and purulent cervical lymphadenitis, 1 of pertussis and 8 of UTI. The clinical efficacy rate was 97.5% (79/81), and bacteriological eradication rate was 100% (76/76). As for side effects, 2 cases of watery stools and 1 case of minor elevation of GPT were observed.
 ...
PMID:[Bacteriological, pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field]. 837 96

The aim of the study was to observe the frequency of occurrence of mycoplasmal antibodies detected by the complement fixation test (CFT), immunoelectroprecipitation test (IEPT) and ELISA in selected groups of patients with respiratory tract infections and to determine the dependence of these antibodies on the age of patients and length of illness. 521 serum samples collected from 404 persons were examined; 378 samples were obtained from 276 patients with pneumonia and 143 from 128 patients with upper respiratory tract infections. Additionally, serum samples from 50 patients with B. pertussis were investigated in this section of the study as a control test to demonstrate the specificity of the tests. It was established that in patients with pneumonia mycoplasmal antibodies are, as a rule, detected in much higher titers than in patients with upper respiratory tract infections. On with age, the level of mycoplasmal antibodies detected in all the three tests rose in the examined patients. In the highest titers antibodies against M. pneumoniae were detected in adults within the age 21-50. As a rule mycoplasmal IgM antibodies reached a level 2-3 times higher than IgG antibodies. It was also shown that already during the first week of illness antibodies against M. pneumoniae determined by the CFT, IEPT and ELISA in the sera of the examined persons are higher than the level known to be diagnostically significant. During the second week of illness IgA and IgM antibodies have a particularly high titer while the growth of titer of IgG antibodies is relatively small. A very high level of IgM, along with progressive growth of IgG antibodies and the related gradual decrease of the index value IgM/IgG, was observed in the serum of patients up to the 4th week of illness. In some cases, in titer known to be diagnostically significant, this high level was present even many months after the appearance of disease symptoms. Antibodies against M. pneumoniae in class of immunoglobulin A disappeared the fastest. Thus it is believed that demonstrating their characteristics dynamics or detecting these antibodies in the patient's serum in the titer assumed to be diagnostically significant can indicate an acute stage of illness.
 ...
PMID:[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infections in humans. II. Occurrence and level of mycoplasma antibodies in patients with respiratory tract infections]. 852 71

Two infants with pneumonia caused by both Bordetella pertussis and respiratory syncytial virus (RS virus) suffered respiratory failure preceded by convulsion. Detection of respiratory pathogens with polymerase chain reaction and enzyme-linked immunosorbent assay was crucial in the management of dually infected infants.
 ...
PMID:Respiratory failure caused by dual infection with Bordetella pertussis and respiratory syncytial virus. 874 24

Respiratory infections, especially community-acquired forms of pneumonia (CAP), are challenging for clinicians because (1) a causative microorganism can only be found in about 50% of cases; (2) initial therapy, therefore, must be based on a probable or most likely etiology in the context of the patient's overall medical condition; and (3) new microbes or those considered previously as normal flora or less virulent forms seem responsible for some cases. It is important to be acquainted with new causes of infection which include Legionella species, Chlamydia pneumoniae, diphtheroids in certain instances (Corynebacterium pseudodiphtheriticum), and viruses such as the Hanta strains. Infections with Bordetella pertussis are increasing. However, the ever present and most common cause of CAP, Streptococcus pneumoniae, continues to present problems because of increasing antibiotic resistance, the high case fatality rate when bacteremia accompanies pneumonia, and the inability to give prophylactic immunization to all people with risk factors for this infection.
 ...
PMID:Respiratory infections: community-acquired pneumonia and newer microbes. 879 Dec 58

In March 1992, March 1993, and June 1994, an international expert advisory committee oversaw a systematic and comprehensive review of potential interventions for preventing pneumonia among children aged less than 5 living in developing countries. The World Health Organization's Programme for the Control of Acute Respiratory Infections (ARIs) and the London School of Hygiene and Tropical Medicine conducted the review. There were 28 individual intervention areas identified among six broad intervention groups. Immunization comprises one of the six broad intervention categories. Specific immunization interventions include increased coverage of measles and pertussis and new vaccines for Pneumococcus, H. influenza B, respiratory syncytial virus, and other viral vaccines. Improving nutrition interventions revolve around breast feeding, low birth weight, malnutrition, vitamin A, severe anemia, and other micronutrients (e.g., zinc). The broad intervention category of reducing environmental pollution encompasses indoor air pollution, environmental tobacco smoke, and outdoor air pollution. Severely malnourished children, high risk neonates, ARI (upper tract), helminths, and wheezing fall under the case management and chemoprophylaxis intervention category. Crowding, direct transmission, and HIV are addressed in the category of reducing transmission of pathogens. The category of improving child care practices includes care-seeking, avoiding chilling, other child care practices, maternal education, and child spacing. The specialists conducted modeling to determine the potential impact of various interventions. It showed that the potential impact of an intervention increases independently with the pre-intervention prevalence of the risk category, with the size of the associated relative risk, and with the reduction in risk-category prevalence achieved by the intervention. Modeling will be used to compare the potential impacts of ARI preventive approaches with the impact achievable with the case management strategy.
 ...
PMID:Potential interventions for the prevention of childhood pneumonia in developing countries: a systematic review. 890 73


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>